Nothing Special   »   [go: up one dir, main page]

JP2524803B2 - Novel camptothecin derivative and method for producing the same - Google Patents

Novel camptothecin derivative and method for producing the same

Info

Publication number
JP2524803B2
JP2524803B2 JP63073426A JP7342688A JP2524803B2 JP 2524803 B2 JP2524803 B2 JP 2524803B2 JP 63073426 A JP63073426 A JP 63073426A JP 7342688 A JP7342688 A JP 7342688A JP 2524803 B2 JP2524803 B2 JP 2524803B2
Authority
JP
Japan
Prior art keywords
fatty acid
producing
acyl group
camptothecin derivative
camptothecin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP63073426A
Other languages
Japanese (ja)
Other versions
JPH01246287A (en
Inventor
善光 長尾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yakult Honsha Co Ltd
Original Assignee
Yakult Honsha Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Co Ltd filed Critical Yakult Honsha Co Ltd
Priority to JP63073426A priority Critical patent/JP2524803B2/en
Publication of JPH01246287A publication Critical patent/JPH01246287A/en
Application granted granted Critical
Publication of JP2524803B2 publication Critical patent/JP2524803B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】 〔産業上の利用分野〕 本発明は医薬もしくはそ中間体として有用なカンプト
テシンの20位水酸基における高級脂肪酸とのエステル誘
導体およびその製造法に関するものである。
DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to an ester derivative of a higher fatty acid at the 20-hydroxyl group of camptothecin, which is useful as a medicine or an intermediate thereof, and a method for producing the same.

〔背景技術〕[Background technology]

カンプトテシンは、落葉喬木喜樹(camptotheca acum
inata)等から抽出、単離されるアルカロイドで、強力
な核酸合成阻害作用を有し、その作用は迅速かつ可逆性
を示すことが特徴であり、既存の抗ガン剤と交叉又耐性
を示さないという独特な作用機作をもつ抗腫瘍性の物質
で、マウスL1210白血病、ラツトのウオーカー256肉腫な
どの実験移植ガンに対し強力な制ガン効果を示すことが
認められているが、毒性作用を有するために、医薬品と
しての有用性がおのずから制限されているのが現状であ
る。
Camptothecin is used in the camptotheca acum
Alkaloids extracted and isolated from inata) etc. have a strong nucleic acid synthesis inhibitory action, and are characterized by rapid and reversible action, and do not show cross-resistance with existing anti-cancer agents. It is an antitumor substance with a unique mechanism of action, and has been shown to have a strong anti-tumor effect on experimental transplant cancers such as mouse L1210 leukemia and rat Walker 256 sarcoma, but it has a toxic effect. At present, the usefulness of the drug is naturally limited.

そこでこのカンプトテシンをその誘導体に変えること
により制ガン活性を保持しながら、毒性の低下を図る試
みが従来なされて来た。しかしながら、カンプトテシン
の各種有機溶剤に対する難溶性や、その構造中のヘテロ
関に由来する親電子置換反応に対する抵抗性などの理由
で、誘導体に変換するにも、種々の障害があり、机上で
企画するほどに新規な誘導体を得ることは容易でないの
が実状である。
Therefore, attempts have been made to reduce toxicity while maintaining anticancer activity by changing this camptothecin to its derivative. However, due to reasons such as poor solubility of camptothecin in various organic solvents and resistance to electrophilic substitution reaction due to the hetero function in its structure, there are various obstacles in converting to derivatives, and it is planned on the desk. In reality, it is not easy to obtain such a novel derivative.

カンプトテシンの20位水酸基についての化学的修飾に
関しては、単純なアシル化(例えば、アセチル化、ヘキ
サノイル化など)が知られている〔例えば、J.Amer.Che
m.Soc.,88,3888(1966)、Phytochemistry,18,1085(19
79)参照〕。このようにして得られた修飾体には、制ガ
ン活性は見られない。また、種々の立体障害を有するア
シル基、もしくは、官能基を有するアシル基は通常の反
応操作では導入することが困難であり、従来、この20位
水酸基の化学的修飾による生理活性や物理的性質の改善
の試みは行うことができない状況にあつた。
Regarding the chemical modification of the 20th hydroxyl group of camptothecin, simple acylation (eg, acetylation, hexanoylation, etc.) is known [eg, J. Amer.
m.Soc., 88,3888 (1966), Phytochemistry, 18,1085 (19
79)]. The modified product thus obtained has no anticancer activity. Further, it is difficult to introduce an acyl group having various steric hindrances or an acyl group having a functional group by a normal reaction operation, and conventionally, physiological activity and physical properties due to the chemical modification of the 20-position hydroxyl group have been conventionally known. There was a situation in which no attempt at improvement could be made.

〔発明の開示〕[Disclosure of Invention]

本発明者は、カンプトテシンの20位における高級脂肪
酸エステルを合成することについて種々検討した結果、
カンプトテシンと高級脂肪酸とを適当な塩基物質の存在
下に、カルボジイミド型の縮合剤で処理することにより
高収率で目的とする20位におけるエステルが得られるこ
とを見出した。
The present inventor, as a result of various studies on synthesizing a higher fatty acid ester at the 20-position of camptothecin,
It was found that the target ester at the 20-position can be obtained in high yield by treating camptothecin and higher fatty acid with a carbodiimide type condensing agent in the presence of a suitable base substance.

すなわち、本発明は、新規化合物として、 一般式(I) (式中R1は炭素原子数16〜20の飽和もしくは不飽和の高
級脂肪酸のアシル基であり、このアシル基は置換基とし
て水酸基を有していてもよい)で表わされるカンプトテ
シンの誘導体を提供するものであり、また、その製造法
として、カンプトテシンと飽和もしくは不飽和の高級脂
肪酸とを塩基物質の存在下に、カルボジイミド化合物を
縮合剤として用いて処理してエステル化することを特徴
とする一般式(II) (式中、R2は飽和もしくは不飽和の高級脂肪酸のアシル
基を示す)で表わされるカンプトテシン誘導体の製造法
を提供するものである。
That is, the present invention provides a novel compound represented by the general formula (I) (Wherein R 1 is an acyl group of a saturated or unsaturated higher fatty acid having 16 to 20 carbon atoms, and the acyl group may have a hydroxyl group as a substituent). In addition, as a method for producing the same, it is generally characterized by treating camptothecin and a saturated or unsaturated higher fatty acid in the presence of a basic substance with a carbodiimide compound as a condensing agent to effect esterification. Formula (II) (Wherein R 2 represents an acyl group of a saturated or unsaturated higher fatty acid), and a method for producing the camptothecin derivative.

上記の製造法において用いられる塩基物質としては、
特定されないが、特に、4−N,N−ジメチルアミノピリ
ジンを用いるのが好ましい。また、カルボジイミド型化
合物の縮合剤としてはエステル化に適する種々のタイプ
のものが知られているが、本発明の上記製造法において
も、特に特定はされないが、ジシクロヘキシルカルボジ
イミドが、好ましく用いられる。
As the basic substance used in the above production method,
Although not specified, it is particularly preferable to use 4-N, N-dimethylaminopyridine. Various types of carbodiimide-type compound condensing agents known to be suitable for esterification are known, but dicyclohexylcarbodiimide is preferably used in the above-mentioned production method of the present invention, although not particularly specified.

また、本発明者らは、上記製造法により得られた不飽
和の高級脂肪酸のエステルを四酸化オスミウムで処理
し、そのアシル基中の不飽和結合に対し、水酸基を導入
して、水酸基を有する飽和脂肪酸のアシル基とし得るこ
とを見出した。すなわち、本発明は、さらに、一般式
(III) (式中、R3は不飽和脂肪酸のアシル基を示す)で表わさ
れるカンプトテシン誘導体を四酸化オスミウムで処理す
ることを特徴とする一般式(IV) (式中、R4は、置換基として水酸基を有する飽和脂肪酸
のアシル基を示す)で表わされるカンプトテシン誘導体
の製造法を提供するものである。
Further, the present inventors treat the ester of unsaturated higher fatty acid obtained by the above-mentioned production method with osmium tetroxide, introduce a hydroxyl group to the unsaturated bond in the acyl group, and have a hydroxyl group. It has been found that it can be used as an acyl group of saturated fatty acid. That is, the present invention further provides a compound represented by the general formula (III) (Wherein R 3 represents an acyl group of an unsaturated fatty acid), the camptothecin derivative is treated with osmium tetroxide and represented by the general formula (IV) (Wherein, R 4 represents an acyl group of a saturated fatty acid having a hydroxyl group as a substituent), and provides a method for producing a camptothecin derivative.

通常、水酸基を有する脂肪酸のアシル基の導入には、
その水酸基に対する保護基の導入さらには、その保護基
の脱離という煩雑な工程を必要とするが、本発明に係る
上記の製造法によれば、簡便な操作をもつて、高収率で
目的とする水酸基を有するアシル基を持つエステルを得
ることができる。
Usually, to introduce an acyl group of a fatty acid having a hydroxyl group,
Introducing a protective group for the hydroxyl group, and further, a complicated step of removing the protective group is required. However, according to the above-mentioned production method of the present invention, a simple operation is performed and a high yield is obtained. An ester having an acyl group having a hydroxyl group can be obtained.

本発明に係る上記の方法により、アシル基中に、2重
結合を1個ないし3個有しているような脂肪酸とのエス
テル誘導体についてその2重結合の個数に対応するモル
数の四酸化オスミウムを用いて反応させることにより、
対応する2重結合の各位置に水酸基を導入することがで
きる。
According to the above method of the present invention, for an ester derivative with a fatty acid having 1 to 3 double bonds in the acyl group, the molar number of osmium tetroxide corresponding to the number of the double bonds. By reacting with
A hydroxyl group can be introduced at each position of the corresponding double bond.

本発明に係る前記式(I)で表わされるカンプトテシ
ン誘導体は、制ガン活性を有しており、また、カンプト
テシンの20位の水酸基を効率的に化学的に修飾する方法
を確立した本発明の方法は、多くの有望な既存の誘導体
に対しても適用が可能である。
The camptothecin derivative represented by the formula (I) according to the present invention has anticancer activity, and the method of the present invention has established a method for efficiently chemically modifying the 20-position hydroxyl group of camptothecin. Is also applicable to many promising existing derivatives.

以下に実施例により本発明を更に詳細に説明するが、
本発明は、かかる実施例に特定されるものではない。
Hereinafter, the present invention will be described in more detail with reference to Examples.
The invention is not limited to such an embodiment.

実施例1 20−O−オレイルカンプトテシン カンプトテシン(1mmol)とオレイン酸(1mmol)、ジ
シクロヘキシルカルボジイミド(1mmol)及び4−N,N−
ジメチルアミノピリジン(触媒量)を塩化メチレンに溶
解し、この混合物を室温で24時間撹拌する。反応混合物
を減圧下に乾固し、残留物をフラツシユカラムクロマト
グラフイ(n−ヘキサン,酢酸エチル,メタノール,4:
5.5:0.5)により精製すると標記化合物を固体として76
%の収率で得る。m.p.78℃1 NMR(200Mz,CDCl3):δ0.85(3H,t,J=0.25)、0.95
(3H,t,J=0.5Hz)、1.25(20H,broad singlet)、1.6
(2H,m)、1.9(4H,m)、2.35(2H,m)、2.45(2H,t,J
=0.25Hz)、5.25(4H,m)、5.4&5.7(2H,d,J=1H
z)、7.22(1H,s)、7.68(1H,t,J=0.5Hz)、7.85(1
H,t,J=0.5Hz)、7.95(1H,d,J=0.5Hz)、8.2(1H,d,J
=0.5Hz)、8.4(1H,d,J=0.5Hz)。
Example 1 20-O-oleylcamptothecin Camptothecin (1 mmol) and oleic acid (1 mmol), dicyclohexylcarbodiimide (1 mmol) and 4-N, N-
Dimethylaminopyridine (catalytic amount) is dissolved in methylene chloride and the mixture is stirred at room temperature for 24 hours. The reaction mixture was evaporated to dryness under reduced pressure, and the residue was subjected to flash column chromatography (n-hexane, ethyl acetate, methanol, 4:
5.5: 0.5) to give the title compound as a solid in 76
Obtained in% yield. mp78 ° C. 1 NMR (200 Mz, CDCl 3 ): δ0.85 (3H, t, J = 0.25), 0.95
(3H, t, J = 0.5Hz), 1.25 (20H, broad singlet), 1.6
(2H, m), 1.9 (4H, m), 2.35 (2H, m), 2.45 (2H, t, J
= 0.25Hz), 5.25 (4H, m), 5.4 & 5.7 (2H, d, J = 1H
z), 7.22 (1H, s), 7.68 (1H, t, J = 0.5Hz), 7.85 (1
H, t, J = 0.5Hz), 7.95 (1H, d, J = 0.5Hz), 8.2 (1H, d, J
= 0.5Hz), 8.4 (1H, d, J = 0.5Hz).

IR(CHCl3,cm-1);1760,1680,1620 実施例2 20−O−(9′,10′−ジヒドロキシ)ステ
アロイルカンプトテシン 実施例1で得られた20−O−オレオイルカンプトテシ
ン(0.4mmol)を、ピリジン(3ml)に溶解し、四酸化オ
スミウム(0.4mmol)を加え、亜硫酸水素ナトリウム(1
57.5mg),水(2.62ml),ピリジン(1.75ml)を加え、
室温で4時間撹拌する。反応混合物が橙色になつた後塩
化メチレンで抽出する。抽出物は、フラツシユカラムク
ロマトグラフイー(n−ヘキサン、酢酸エチル、メタノ
ール、2:7.5:0.5)により精製すると、標記化合物が白
色の粉末として得られる。収率45%m.p.106℃1NMR(200
Mz,CDCl3):δ0.85(3H,t,J=0.25Hz)、0.95(3H,t,J
=0.5Hz)、1.3(24H,broad singlet)、1.6(2H,m)、
1.8(2H,unresolved signal)、2.2(2H,m)、2.45(2
H,t,J=0.25Hz)、3.5(2.H,m)、5.25(2H,s)、5.4&
5.7(2H,d,two doublets,J=1Hz)、7.18(1H,s)、7.6
(1H,t,J=0.5Hz)、7.7(1H,t,J=0.5Hz)、7.9(1H,
d,J=0.5Hz)、8.15(1H,d,J=0.5Hz)、8.35(1H,
s)。
IR (CHCl 3 , cm −1 ); 1760,1680,1620 Example 2 20-O- (9 ′, 10′-dihydroxy) stearoylcamptothecin 20-O-oleoylcamptothecin obtained in Example 1 (0.4 mmol) ) Was dissolved in pyridine (3 ml), osmium tetroxide (0.4 mmol) was added, and sodium bisulfite (1
57.5mg), water (2.62ml), pyridine (1.75ml),
Stir at room temperature for 4 hours. After the reaction mixture turns orange, it is extracted with methylene chloride. The extract is purified by flash column chromatography (n-hexane, ethyl acetate, methanol, 2: 7.5: 0.5) to give the title compound as a white powder. Yield 45% mp 106 ° C 1 NMR (200
Mz, CDCl 3 ): δ0.85 (3H, t, J = 0.25Hz), 0.95 (3H, t, J
= 0.5Hz), 1.3 (24H, broad singlet), 1.6 (2H, m),
1.8 (2H, unresolved signal), 2.2 (2H, m), 2.45 (2
H, t, J = 0.25Hz), 3.5 (2.H, m), 5.25 (2H, s), 5.4 &
5.7 (2H, d, two doublets, J = 1Hz), 7.18 (1H, s), 7.6
(1H, t, J = 0.5Hz), 7.7 (1H, t, J = 0.5Hz), 7.9 (1H, t
d, J = 0.5Hz), 8.15 (1H, d, J = 0.5Hz), 8.35 (1H,
s).

IR(CHCl3,cm-1):3600,1780,1700,1650。 IR (CHCl 3, cm -1) : 3600,1780,1700,1650.

MS:647(M+1,C38H51O7N2)。MS: 647 (M + 1, C 38 H 51 O 7 N 2).

実施例3 20−O−リノレオイルカプトテシン 実施例1におけるオレイン酸に代えてリノール酸を用
い、実施例1と同様の操作により反応を行い、フラツシ
ユカラムクロマトグラフイー(n−ヘキサン,酢酸エチ
ル、1:3)により精製することにより標記化合物を59%
の収率で得た。m.p.81℃1 NMR(200Mz,CDCl3);δ0.85(3H,t,J=0.25Hz)、0.9
5(3H,t,J=0.5Hz)、1.25(14H,broad singlet)、1.6
5(2H,m)、1.95(4H,m)、2.2(2H,m)、2.45(2H,t,J
=0.25Hz)、2.7(2H,t,J=0.25Hz)、5.25(6H,m)、
5.4&5.65(2H,two doublets,J=1Hz)、7.2(1H,s)、
7.65(1H,t,J=0.5Hz)、7.8(1H,t,J=0.5Hz)、7.95
(1H,d,J=0.5Hz)、8.2(1H,d,J=0.5Hz)、8.38(1H,
s)。
Example 3 20-O-Linoleoylcaptothecin Using linoleic acid in place of oleic acid in Example 1, the reaction was carried out in the same manner as in Example 1, and flash column chromatography (n-hexane, acetic acid). 59% of the title compound by purification with ethyl, 1: 3)
It was obtained in a yield of. mp81 ° C 1 NMR (200Mz, CDCl 3 ); δ0.85 (3H, t, J = 0.25Hz), 0.9
5 (3H, t, J = 0.5Hz), 1.25 (14H, broad singlet), 1.6
5 (2H, m), 1.95 (4H, m), 2.2 (2H, m), 2.45 (2H, t, J
= 0.25Hz), 2.7 (2H, t, J = 0.25Hz), 5.25 (6H, m),
5.4 & 5.65 (2H, two doublets, J = 1Hz), 7.2 (1H, s),
7.65 (1H, t, J = 0.5Hz), 7.8 (1H, t, J = 0.5Hz), 7.95
(1H, d, J = 0.5Hz), 8.2 (1H, d, J = 0.5Hz), 8.38 (1H,
s).

IR(CHCl3,cm-1):1745,1670,1620 MS:610(M+,C38H46O5N2)。 IR (CHCl 3, cm -1) : 1745,1670,1620 MS: 610 (M +, C 38 H 46 O 5 N 2).

実施例4 20−O−(9′,10′,12′,13′−テトラヒ
ドロキシ)ステアロイルカンプトテシン 実施例2における20−O−オレオイルカンプトテシン
に代えて、実施例3で得られたリノレオイルカンプトテ
シンを用い、実施例2で述べた方法に準拠して反応を行
い、フラツシユカラムクロマトグラフイー(酢酸エチ
ル、メタノール、1:0.1)により精製し、標記化合物を5
7%の収率で得た。m.p.108℃1 NMR(200Mz,CDCl3):δ0.78(3H,unresolved triple
t)、0.9(3H,t,J=0.5Hz)、1.25(14H,broad single
t)、1.6(6H,m)、1.88(2H,m)、2.2(2H,m)、2.42
(2H,m)、3.5(4H,m)、3.75(2H,m)、4.1(2H,s)、
5.2(2H,s)、5.35&5.62(2H,two doublets,J=1H
z)、7.15(1H,s)、7.6(1H,t,J=0.5Hz)、7.75(1H,
t,J=0.5Hz)、7.9(1H,d,J=0.5Hz)、8.15(1H,d,J=
0.5Hz)、8.32(1H,s)。
Example 4 20-O- (9 ', 10', 12 ', 13'-Tetrahydroxy) stearoylcamptothecin The 20-O-oleoylcamptothecin in Example 2 was replaced with the linoleoyl obtained in Example 3. The reaction was performed according to the method described in Example 2 using camptothecin and purified by flash column chromatography (ethyl acetate, methanol, 1: 0.1) to give the title compound
Obtained in a yield of 7%. mp108 ℃ 1 NMR (200Mz, CDCl 3 ): δ0.78 (3H, unresolved triple
t), 0.9 (3H, t, J = 0.5Hz), 1.25 (14H, broad single
t), 1.6 (6H, m), 1.88 (2H, m), 2.2 (2H, m), 2.42
(2H, m), 3.5 (4H, m), 3.75 (2H, m), 4.1 (2H, s),
5.2 (2H, s), 5.35 & 5.62 (2H, two doublets, J = 1H
z), 7.15 (1H, s), 7.6 (1H, t, J = 0.5Hz), 7.75 (1H, s)
t, J = 0.5Hz), 7.9 (1H, d, J = 0.5Hz), 8.15 (1H, d, J =
0.5Hz), 8.32 (1H, s).

IR(CHCl3,cm-1):3460,1745,1670,1620。 IR (CHCl 3, cm -1) : 3460,1745,1670,1620.

実施例5 20−O−リノレノイルカンプトテシン 実施例1におけるオレイン酸に代えてリノレン酸を用
い、実施例1と同様の操作により反応を行い、フラツシ
ユカラムクロモタグラフイー(n−ヘキサン、酢酸エチ
ル、1:3)により精製することにより標記化合物を60%
の収率で得た。m.p.77℃1 NMR(200Mz,CDCl3):δ0.9(6H,m)、1.25(10H,broa
d singlet)、1.6(2H,m)、2.1(6H,m)、2.45(2H,
m)、2.75(2H,m)、5.25(8H,m)、5.35&5.68(2H,tw
o doublets,J=1Hz)、7.2(1H,s)、7.65(1H,t,J=0.
5Hz)、7.8(1H,t,J=0.5Hz)、7.92(1H,d,J=0.5H
z)、8.2(1H,d,J=0.5Hz)、8.38(1H,s)。
Example 5 20-O-Linolenoylcamptothecin Using linolenic acid in place of oleic acid in Example 1, the reaction was carried out in the same manner as in Example 1, and the flash column chromotagraphie (n-hexane, acetic acid was used. 60% of the title compound by purification with ethyl, 1: 3)
It was obtained in a yield of. mp77 ° C 1 NMR (200Mz, CDCl 3 ): δ0.9 (6H, m), 1.25 (10H, broa
d singlet), 1.6 (2H, m), 2.1 (6H, m), 2.45 (2H, m
m), 2.75 (2H, m), 5.25 (8H, m), 5.35 & 5.68 (2H, tw
o doublets, J = 1Hz), 7.2 (1H, s), 7.65 (1H, t, J = 0.
5Hz), 7.8 (1H, t, J = 0.5Hz), 7.92 (1H, d, J = 0.5H)
z), 8.2 (1H, d, J = 0.5Hz), 8.38 (1H, s).

IR(CHCl3,cm-1:1750,1670,1610 MS:608(M+,C38H44O5N2)。 IR (CHCl 3, cm -1: 1750,1670,1610 MS: 608 (M +, C 38 H 44 O 5 N 2).

Claims (5)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】一般式(I) (式中R1は炭素原子数16〜20の飽和もしくは不飽和の高
級脂肪酸のアシル基であり、このアシル基は置換基とし
て水酸基を有していてもよい)で表わされるカンプトテ
シンの誘導体。
1. A general formula (I) (In the formula, R 1 is an acyl group of a saturated or unsaturated higher fatty acid having 16 to 20 carbon atoms, and the acyl group may have a hydroxyl group as a substituent).
【請求項2】カンプトテシンと飽和もしくは不飽和の高
級脂肪酸とを塩基物質の存在下に、カルボジイミド化合
物を縮合剤として用いて処理してエステル化することを
特徴とする一般式(II) (式中、R2は飽和もしくは不飽和の高級脂肪酸のアシル
基を示す)で表わされるカンプトテシン誘導体の製造
法。
2. A general formula (II) characterized in that camptothecin and a saturated or unsaturated higher fatty acid are treated with a carbodiimide compound as a condensing agent in the presence of a basic substance for esterification. (Wherein R 2 represents an acyl group of a saturated or unsaturated higher fatty acid), and a method for producing a camptothecin derivative.
【請求項3】前記のカルボジイミド化合物がジシクロヘ
キシルカルボジイミドである請求項2記載のカンプトテ
シン誘導体の製造法。
3. The method for producing a camptothecin derivative according to claim 2, wherein the carbodiimide compound is dicyclohexylcarbodiimide.
【請求項4】前記の塩基物質が、4−N,N−ジメチルア
ミノピリジンである請求項2もしくは請求項3記載のカ
ンプトテシン誘導体の製造法。
4. The method for producing a camptothecin derivative according to claim 2, wherein the basic substance is 4-N, N-dimethylaminopyridine.
【請求項5】一般式(III)、 (式中、R3は不飽和脂肪酸のアシル基を示す)で表わさ
れるカンプトテシン誘導体を四酸化オスミウムで処理す
ることを特徴とする一般式(IV) (式中、R4は、置換基として水酸基を有する飽和脂肪酸
のアシル基を示す)で表わされるカンプトテシン誘導体
の製造法。
5. General formula (III), (Wherein R 3 represents an acyl group of an unsaturated fatty acid), the camptothecin derivative is treated with osmium tetroxide and represented by the general formula (IV) (In the formula, R 4 represents an acyl group of a saturated fatty acid having a hydroxyl group as a substituent), and a method for producing a camptothecin derivative.
JP63073426A 1988-03-29 1988-03-29 Novel camptothecin derivative and method for producing the same Expired - Lifetime JP2524803B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP63073426A JP2524803B2 (en) 1988-03-29 1988-03-29 Novel camptothecin derivative and method for producing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63073426A JP2524803B2 (en) 1988-03-29 1988-03-29 Novel camptothecin derivative and method for producing the same

Publications (2)

Publication Number Publication Date
JPH01246287A JPH01246287A (en) 1989-10-02
JP2524803B2 true JP2524803B2 (en) 1996-08-14

Family

ID=13517900

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63073426A Expired - Lifetime JP2524803B2 (en) 1988-03-29 1988-03-29 Novel camptothecin derivative and method for producing the same

Country Status (1)

Country Link
JP (1) JP2524803B2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731316A (en) * 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
TW464652B (en) * 1996-10-30 2001-11-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
ID23424A (en) 1997-05-14 2000-04-20 Bayer Ag GLIKOKONJUGUS OF 20 (S) -CAMPTOTESIN
YU64602A (en) 2000-02-28 2005-06-10 Aventis Pharma S.A. A composition comprising camptothecin and a pyramidine derivative for the treatment of cancer
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
AU2002216029B2 (en) 2000-10-27 2006-01-05 Pfizer, Inc. A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
US6350756B1 (en) * 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US20060003976A1 (en) * 2004-06-04 2006-01-05 Yuehua Zhang Cholesterol/bile acid/bile acid derivative-modified therapeutic drug compounds

Also Published As

Publication number Publication date
JPH01246287A (en) 1989-10-02

Similar Documents

Publication Publication Date Title
JP2708346B2 (en) Baccatin III derivative, method for producing the same, and antitumor agent containing the same
GB2056973A (en) Camptothecin derivatives useful as antitumour agents
JP2524803B2 (en) Novel camptothecin derivative and method for producing the same
JPS6150985A (en) Novel camptothecin derivative
US5750562A (en) 10-deacetylbaccatine III and 10-deacetyl 14β-hydroxybaccatine III derivatives, a process for the preparation thereof and pharmaceutical compositions containing them
JP2524804B2 (en) Novel camptothecin derivative and method for producing the same
Yang et al. A mild and one-step synthesis of 2, 8-dioxabicyclo [3.3. 1] nonane derivatives via classical Knoevenagel condensation
JP3423002B2 (en) Taxane derivatives, their preparation, and formulations containing them
DE60104281T2 (en) SEMI-SYNTHETIC TAXANES WITH ANTITUMOR AND ANTIANGIOGENETIC EFFECT
CN108864148B (en) Rapamycin-40-malic acid sodium salt and preparation method and application thereof
JPS5839684A (en) Preparation of 10-substituted camptothecin derivative
CN105985401B (en) Tripterine derivative, preparation method and application thereof
CN110759961B (en) Ursolic acid indolyquinone amide derivatives and preparation method and application thereof
EP0207336B1 (en) Nitro derivatives of vinblastine-type bis-indoles, a process for preparing same and pharmaceutical compositions containing them
JP2000503666A (en) Camptothecin isolated from Mappia foetida-backbone compounds and their use as synthons for novel pharmaceutical and therapeutic agents
JPH0615546B2 (en) Novel camptothecin derivative
JPH0931092A (en) Production of 2'-3'-di-o-acyl atp
US4895852A (en) Antitumor alkaloids
CN109575051B (en) Natural medicine component modified derivative and anti-tumor application thereof
EP0205168B1 (en) Furfuryl derivatives of vinblastine-type bis-indoles, a process for preparing same and pharmaceutical compositions containing them
JP4334194B2 (en) Echinasaidin 786 and method for obtaining the same
EP0205169B1 (en) Bis-indole derivatives, process for preparing same and pharmaceutical compositions containing them
JP2640239B2 (en) Protostar-13 (17) ene-3,16-dione compound
JPH0369912B2 (en)
Bransova et al. Preparation and Study of Reactions of the 5-Substituted 4-Oxo-4H-pyran-2-carboxylic Acid

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term